NICE has extended the number of patients eligible for treatment with Pfizer’s oral antiviral Paxlovid by around 1.4 million, as millions of doses of the COVID-19 therapy a
The COVID-19 pandemic was a calamity in more ways than one: lost lives, shuttered businesses, closed borders, broken supply chains, joblessness, and frayed social unity.
COVID-19 vaccines are not as effective in immunocompromised individuals as they are in the general population, due to an inability to produce a robust protective response to the vaccine.
Japan’s medicines regulator has approved the first vaccine based on self-assembling RNA, a spin on the mRNA technology used in current shots, which is designed to deliver
A combination COVID-19 and influenza vaccine being developed by Pfizer and BioNTech has generated immune responses against the viruses in a phase 1/2 trial, setting up a p
Pfizer has revealed what it will charge for a five-day course of its oral antiviral Paxlovid for COVID-19 when it starts to see it on the commercial market later this year